WikiPsiquiatria - Posts previos
Mostrando entradas con la etiqueta Antidepressants. Mostrar todas las entradas
Mostrando entradas con la etiqueta Antidepressants. Mostrar todas las entradas

New antidepressants can increase risks for elderly, study suggests

ScienceDaily (Aug. 3, 2011) — Older people taking new generation antidepressants are at more risk of dying or suffering from a range of serious health conditions including stroke, falls, fractures and epilepsy, suggests a new study involving researchers at The University of Nottingham.

The research, published on the British Medical Journal website, discovered that selective serotonin reuptake inhibitors (SSRIs) are more strongly associated with an increased risk of several adverse outcomes in people over the age of 65 with depression compared with older tricyclic antidepressants (TCAs).

The authors say the risks and benefits of different antidepressants should be carefully considered when prescribing these drugs to elderly patients and have called for further research to investigate the findings.

Dr Carol Coupland, Associate Professor in Medical Statistics in The University of Nottingham's Division of Primary Care said: "We've found some evidence from our study that the older tricyclic antidepressants may be associated with lower risks of several adverse outcomes compared with newer antidepressants in older people diagnosed as having depression.

"This was an unexpected finding, and so further research using other data sources is needed to confirm these findings as well as provide more evidence on the benefits of different antidepressants in this group of people."

Depression is a common condition in older people and antidepressants -- particularly SSRIs -- are widely used. However, very little is known about the safety of these drugs in older people.

The team of researchers from the Universities of Nottingham and East Anglia set out to investigate the potential link between antidepressant treatment and the risk of a number of potentially life-threatening outcomes in older people.

They identified 60,746 UK patients aged 65 and over with a newly diagnosed episode of depression between 1996 and 2007 using the QResearch primary care database. Many patients had other conditions, such as heart disease and diabetes, and were taking several medications.

Patients were tracked until the end of 2008. During this time, 89 per cent (54,038) received at least one prescription for an antidepressant, and a total of 1,398,359 prescriptions for antidepressants were received. Of these 57 per cent were for SSRIs, 31 per cent for TCAs, 0.2 per cent for monoamine oxidase inhibitors (MAOIs) and 13.5 per cent for other antidepressants.

Antidepressant use was then analysed against several adverse outcomes including all-cause mortality, attempted suicide or self harm, heart attack, stroke, falls, fractures, epilepsy or seizures and high salt levels in the blood (hyponatraemia).

After adjusting for factors that could affect the results, including age, sex, severity of depression, other illnesses and use of other medications, the team found that SSRIs and drugs in the group of other antidepressants were associated with an increased risk of several adverse outcomes compared with TCAs.

Those taking SSRIs were more likely to die, suffer a stroke, fall or fracture, have epilepsy or a seizure and have hyponatraemia compared with TCAs. The group of other antidepressants were associated with an increased risk of mortality, attempted suicide or self-harm, stroke, fracture and epilepsy or seizures.

Patients in the study had a seven per cent risk of dying over one year while they were not taking antidepressants, while the comparable risks were 8.1 per cent when taking TCAs, 10.6 per cent for SSRIs and 11.4 per cent for the group of other antidepressants. For stroke, one-year risks were 2.3 per cent, 2.6 per cent and three per cent (compared with 2.2 per cent when not on antidepressants) and for fracture they were 2.2 per cent, 2.7 per cent and 2.8 per cent compared with 1.8 per cent.

Among individual drugs trazodone, mirtazapine and venlafaxine carried the highest risk for some adverse outcomes.

Rates of most adverse outcomes were highest in the 28 days after starting the antidepressant and also in the 28 days after stopping.

The authors also point out that TCAs were prescribed at lower doses than SSRIs and other antidepressant drugs, which they say "could in part explain our findings." They also caution that differences between patients prescribed different antidepressant drugs may account for some of the associations seen in the study, underlining the need for further research to confirm the findings.

Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by University of Nottingham, via AlphaGalileo.

Journal Reference:

C. Coupland, P. Dhiman, R. Morriss, A. Arthur, G. Barton, J. Hippisley-Cox. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ, 2011; 343 (aug02 1): d4551 DOI: 10.1136/bmj.d4551

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.



View the original article here sciencedaily.com

Parkinson's Patients Get No Benefit From Antidepressants Sertraline Or Mirtazapine, But Have More Side Effects


Editor's Choice
Academic Journal
Main Category: Parkinson's Disease
Also Included In: Depression;  Psychology / Psychiatry
Article Date: 19 Jul 2011 - 15:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
3 starsnot yet rated
Two antidepressants prescribed often for individuals with Parkinson's disease - sertraline or mirtazapine - were found to have no benefits for such patients. In fact, they also experienced unpleasant side effects., according to the results of the HTA-SADD trial published in The Lancet. The article was written by Professor Sube Banerjee and team, Institute of Psychiatry, King's College London, UK.

The trial involved 325 patients from nine different centers in England. They all had either possible Alzheimer's disease, depression which had lasted at least 4 weeks, or a dementia-related depression above a certain score. Any patient who was a suicide risk, contraindicated for the drugs, was already on antidepressants, or was at the time already taking part in another trial, was ineligible for this study.

They were randomly selected into one of three groups: Sertraline group - 150mg per day - 107 patientsMirtazapine group - 45 mg per day - 107 patientsControl group - placebo - 111 patientsThe researchers were focusing (primary outcome) on how much depression might be reduced after 13 weeks of treatment. They all also received standard care.

At 13 weeks there were no differences in the depression scores among the three groups, not even at 39 weeks.

26% of those on the placebo group experienced adverse reactions, compared to 43% in the sertraline group and 41% in the mirtazapine group. By week 39 five participants had died in each group.

The researchers concluded:

"The two classes of antidepressants most likely to be prescribed for depression in Alzheimer's disease are no more effective than placebo. In our study, there were more adverse reactions in individuals treated with antidepressants than there were with placebo. Clinicians and investigators need to reframe the way they think about the treatment of people with Alzheimer's disease who are depressed, and reconsider routine prescription of antidepressants."

Dr Henry Brodaty, Brain and Ageing Research Program and Primary Dementia Collaborative Research Centre, University of New South Wales, Sydney, Australia, concluded in a Comment in the same journal:

"The HTA-SADD trial has underscored the need for clinicians to think about creative alternatives to drug treatment for management of depression in people with dementia, and to use evidence-based techniques and partnerships with family carers."

"Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial"
Prof Sube Banerjee MD, Jennifer Hellier MSc, Michael Dewey PhD, Renee Romeo PhD, Clive Ballard MD, Robert Baldwin MD, Peter Bentham MRCPsych, Chris Fox MD, Clive Holmes PhD, Cornelius Katona MD, Martin Knapp PhD, Claire Lawton FRCPsych, James Lindesay DM, Gill Livingston MD, Niall McCrae PhD, Esme Moniz-Cook PhD, Joanna Murray MA, Shirley Nurock MSc, Martin Orrell PhD, John O'Brien DM, Michaela Poppe PhD, Alan Thomas PhD, Rebecca Walwyn PhD, Kenneth Wilson MD, Alistair Burns MD

The Lancet, Early Online Publication, 18 July 2011 doi:10.1016/S0140-6736(11)60830-1

Written by Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Please rate this article:
(Hover over the stars
then click to rate) Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.




View the original article here

Medscape Psychiatry

Scientific American - Mind & Brain

Nature Reviews Neuroscience - Issue - nature.com science feeds

Nature Reviews Neuroscience - AOP - nature.com science feeds

Nature Neuroscience - Issue - nature.com science feeds

Nature Neuroscience - AOP - nature.com science feeds

Translational Psychiatry

Neuropsychopharmacology - AOP - nature.com science feeds

Neuropsychopharmacology - Issue - nature.com science feeds